The ongoing global COVID-19 pandemic requires novel prevention methods. In response, scientists have developed a nasal spray containing human IgG1 antibodies against SARS-CoV-2. This groundbreaking nasal spray serves a dual function in boosting host defenses, neutralizing the virus while forming a protective barrier on the nasopharyngeal mucosa. Preliminary data show that the spray exhibits broad neutralizing activities and has been well tolerated in healthy volunteers. Thorough safety assessments thereby validate its use for human application. Moreover, the nasal spray has proven significantly effective in increasing neutralizing antibodies within nasal fluids. These effects were found to last for up to 6 hours after administration. However, the nasal spray is not intended as an all-encompassing safeguard against the virus. Effective prevention requires that the spray be utilized as part of a broader set of preventative measures. So while the spray shows promise, further study is needed to confirm its use in combating COVID-19.